June 30th 2025
Renier Brentjens, MD, PhD, invited to address Damon Runyon Foundation, New York Academy of Sciences
June 23rd 2025
Roswell Park Comprehensive Cancer Center has been added to Newsweek’s list of America’s Best Cancer Hospitals for 2025.
June 19th 2025
Cancer center's Chief Strategy Officer and Chair of Thoracic Surgery joins prestigious organization
June 16th 2025
Experts from Roswell Park shared findings on these topics at the 2025 ASCO Annual Meeting.
May 30th 2025
Faculty from Roswell Park Comprehensive Cancer Center are among the experts invited to share their research findings at the 2025 ASCO Annual Meeting.
May 19th 2025
Collaborative Roswell Park/Columbia research uncovers greater risk of relapse and complications, lower survival rates.
May 12th 2025
The ongoing phase 2B SURVIVE clinical trial of SurVaxM in glioblastoma will continue following an interim analysis of trial data.
April 24th 2025
Researchers from Roswell Park Comprehensive Cancer Center will report their latest findings to colleagues at the 2025 AACR Annual Meeting.
April 10th 2025
Roswell Park Comprehensive Cancer Center achieved textbook outcomes for 90% of 150 robot-assisted minimally invasive esophagectomies from 2020-2024.
April 8th 2025
Sayan Chakraborty, PhD and team focus on targeting agrin, a protein that promotes treatment resistance/relapse.
April 3rd 2025
Roswell Park-led study takes a significant step toward relief without opioid.
March 25th 2025
Roswell Park Comprehensive Cancer Center surgeons will share their expertise during the 2025 annual meeting of the Society of Surgical Oncology.
March 6th 2025
Roswell Park’s Dr Kenan Onel leads large international team that sheds light on pineoblastoma and Wilms tumor.
February 19th 2025
The GVHD Alliance honored Shernan Holtan, MD, of Roswell Park Comprehensive Cancer Center, as the recipient of the 2025 Lukas D. Wartman Award.
February 17th 2025
CDK2 regulates the cell cycle and may have the potential to drive therapeutic resistance to common breast cancer drugs — including CDK4/6 inhibitors.
January 20th 2025
Laboratory research led by Anna Bianchi-Smiraglia, PhD, reveals therapeutic target in metabolic enzyme IMPDH2.
December 20th 2024
A preclinical study showed gilteritinib can strengthen CAR T-cell therapy in two high-risk pediatric leukemias.
December 16th 2024
Sessions at San Antonio Breast Cancer Symposium address exercise, cannabis, sexual health, plus insights on treatment.
December 5th 2024
Roswell Park CEO Candace S. Johnson, PhD, introduces center’s first Physician in Chief, leaders in strategic areas
November 28th 2024
A treatment approach developed at Roswell Park Comprehensive Cancer Center has shown promising results in a phase 1 clinical trial for patients with TNBC.